The notion that TP53 mutation is required to allow survival of BRCA-deficient ovarian precursor lesions is consistent with the extremely high rates of TP53 mutation in breast cancers arising in BRCA1 mutant women [34,35]. This evidence concerns the gene BRCA1 and breast carcinoma.